| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/18/2006 | WO2005099776A3 Steroid sparing agents and methods of using same |
| 05/18/2006 | WO2005097086A3 Use of 5,10-methylene tetrahydrofolate for the treatment of cancer |
| 05/18/2006 | WO2005092347A3 Anhydrous pharmaceutical composition associating a siliconated agent and solubilised active principle |
| 05/18/2006 | WO2005092040A3 A formulation for increasing endogenous adiponectin and leptin production |
| 05/18/2006 | WO2005089804A3 Combinations of hmg-coa reductase inhibitors and alpha1 adrenergic receptor antagonists |
| 05/18/2006 | WO2005086871A3 Compounds, compositions and methods for inhibiting or treating hiv-1 |
| 05/18/2006 | WO2005082884A3 2-pyridin-2yl-pyrimidine derivatives useful in the treatment of gastro-esophagea l reflux disease |
| 05/18/2006 | WO2005079804A8 Method of stimulating hair growth |
| 05/18/2006 | WO2005069758A3 Frequency assisted transdermal agent delivery method and system |
| 05/18/2006 | WO2005067537A3 Muscarinic acetylcholine receptor antagonists |
| 05/18/2006 | WO2005065158A3 A stabilized sunscreen composition having a particulate inorganic sunscreen |
| 05/18/2006 | WO2005063231A3 Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or esther thereof |
| 05/18/2006 | WO2005058280A3 Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure |
| 05/18/2006 | WO2005051353A8 Pharmaceutical formulations comprising voriconazole |
| 05/18/2006 | WO2005051301A3 Heterocyclic inhibitors of mek and methods of use thereof |
| 05/18/2006 | WO2005041902A3 Anion-binding polymers and uses thereof |
| 05/18/2006 | WO2005035550A3 Dual phase-pna conjugates for the delivery of pna through the blood brain barrier |
| 05/18/2006 | WO2005032484A9 Alkoxy substituted imidazoquinolines |
| 05/18/2006 | WO2005027842A8 Combinations of drugs for the treatment of neoplasms |
| 05/18/2006 | WO2005016269A3 Methods for treating metabolic syndrome |
| 05/18/2006 | WO2005013919A3 Treatment using dantrolene |
| 05/18/2006 | WO2005012544A3 Methods for the identification of inhibitors of mannosyltransferase and mannosyltransferase complex subunit as antibiotics |
| 05/18/2006 | WO2005009451A9 Bacteriophage-containing therapeutic agents |
| 05/18/2006 | WO2004110355A3 Compositions and methods including a recombinant human mab that promotes cns remyelination |
| 05/18/2006 | WO2004091545A3 Selectively inhibiting estrogen production and providing estrogenic effects in the human body |
| 05/18/2006 | WO2004091533A3 Delivery systems of homogeneous, thermoreversible gel film containing kappa-2 carrageenan |
| 05/18/2006 | WO2004091532A3 Homogeneous, thermoreversible gel containing reduced viscosity carrageenan and products made therefrom |
| 05/18/2006 | WO2004074445A3 Model for studying the role of genes in tumor resistance to chemotherapy |
| 05/18/2006 | WO2004014306A3 Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation |
| 05/18/2006 | WO2002049619A9 Induced phase transition method for the production of microparticles containing hydrophilic active agents |
| 05/18/2006 | US20060106256 e.g. 1-[(benzylamino)methyl]-3-(3,5-difluorophenyl)-2-({3-[(dipropylamino)carbonyl]benzoyl}amino)propyl 4-nitrophenyl carbonate; secretase inhibitors; neurodegenerative disorders; Alzheimer's, Parkinson's diseases, Down syndrom, Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type |
| 05/18/2006 | US20060106245 Novel intermediates for use in retinoid synthesis |
| 05/18/2006 | US20060106232 atorvastatin hemi-calcium Form X and solvates of given powder X-ray diffraction pattern; small particle size distribution; dosage forms |
| 05/18/2006 | US20060106231 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| 05/18/2006 | US20060106228 Process for preparing 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl) ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide |
| 05/18/2006 | US20060106225 N3 alkylated benzimidazole derivatives as MEK inhibitors |
| 05/18/2006 | US20060106222 Aminoadamantane derivatives as therapeutic agents |
| 05/18/2006 | US20060106221 Process for the preparation of thiazolidinedione derivatives |
| 05/18/2006 | US20060106220 Compositions and therapeutic methods involving isoflavones and analogues thereof |
| 05/18/2006 | US20060106218 Substituted piperazines |
| 05/18/2006 | US20060106217 Novel compounds and their uses |
| 05/18/2006 | US20060106214 3-isobutyl-8-(6-methoxy-isoquinolin-4-ylmethyl)-1-methyl-3, 7-dihydro-purine-2,6-dione; sexual dysfunction, premature labour, dysmenorrhoea, benign prostatic hyperplasia, bladder outlet obstruction, incontinence, (Prinzmetal) angina, hipotensive agent |
| 05/18/2006 | US20060106213 New Medicaments for the Treatment of Chronic Obstructive Pulmonary Disease |
| 05/18/2006 | US20060106212 6-halo-5-ulosonic acid ester with a 2-aminoalkanethiol form a thiazine ring; reduction and cyclization to form a lactam; reduction and deprotection; Selective alpha glycosidase inhibitors; rigidity of bicyclic ring; industrial scale; 1,5-dideoxy-1,5-imino functionality; glycosyltransferase inhibitors |
| 05/18/2006 | US20060106196 treatment or prophylaxis of cancer using proteins or peptides that elicit T cell mediated immunity; vaccination |
| 05/18/2006 | US20060106117 Compound and method for prevention and/or treatment of vaginal infections |
| 05/18/2006 | US20060106116 Composition for lessening oxidative stress |
| 05/18/2006 | US20060106115 Osteogenesis promoter containing beta-cryptoxanthin as the active ingredient |
| 05/18/2006 | US20060106114 Tertiary amino compounds having opioid receptor affinity |
| 05/18/2006 | US20060106113 Method of delaying ejaculation |
| 05/18/2006 | US20060106112 Treating neurological disorders using selective antagonists of persistent sodium current |
| 05/18/2006 | US20060106111 Phenylnaphthalene compounds |
| 05/18/2006 | US20060106110 Modified amino acid is N-(-5-chlorosalicyloyl)-8-aminocaprylic acid; active agents are heparin, insulin, parathyroid hormone, calcitonin; cardiovascular disorders |
| 05/18/2006 | US20060106109 Short term treatment for uterine disorder |
| 05/18/2006 | US20060106108 Method for scavenging radicals with urocanic acid, derivatives and analogues |
| 05/18/2006 | US20060106107 L-tartrate salt of N-1-Adamantyl-2-{3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)propyl] phenyl}acetamide |
| 05/18/2006 | US20060106106 Beta-hydroxyphenylalkylamines and their use for treating glaucoma |
| 05/18/2006 | US20060106105 Process for making polymorphic form a of 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy] butyric acid |
| 05/18/2006 | US20060106104 Ophthalmic compositions and methods for treating eyes |
| 05/18/2006 | US20060106103 administering 3-(2,2,2-Trifluoro-acetylamino) -benzoic acid 2-oxo-2-phenyl-ethyl ester, for the treatment of epileptic conditions in mammals; antiepileptic agents |
| 05/18/2006 | US20060106102 Napththalene derivatives which inhibit the cytokine or biological activity of microphage migration inhibitory factor (mif) |
| 05/18/2006 | US20060106101 New double salts of (-)-hydroxycitric acid and a process for preparing the same |
| 05/18/2006 | US20060106100 Cyclic palladium compounds having coordinated thereto bis (diphenylphosphine) ferrocene ligands which inhibit the activity of proteins and enzymes and treatment of diseases and disorders associated therewith |
| 05/18/2006 | US20060106099 Novel inhibitors of ubiquitin isopeptidases |
| 05/18/2006 | US20060106098 Andrographolide and its derivatives as TNF-alpha antagonists |
| 05/18/2006 | US20060106097 Metabolism-modulating agents and uses therefor |
| 05/18/2006 | US20060106096 6-[(Anilinocarbonyl)amino]-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-2-carboxamide hydrochloride; treatment of dementia, attention deficit hyperactivity disorder and impairments of learning and memory |
| 05/18/2006 | US20060106095 Therapeutic agent for renal failure |
| 05/18/2006 | US20060106094 Synthetic discodermolide analogs |
| 05/18/2006 | US20060106093 Formulation and delivery method to enhance antioxidant potency of Vitamin E |
| 05/18/2006 | US20060106092 Procyanidin B dimers for aromatase inhibition |
| 05/18/2006 | US20060106091 Antigiardial agents and use thereof |
| 05/18/2006 | US20060106090 Cytotoxic agents comprising taxanes and their therapeutic use |
| 05/18/2006 | US20060106089 Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use |
| 05/18/2006 | US20060106088 Compounds for inflammatory bowel disease treatment with prodrug |
| 05/18/2006 | US20060106087 Benzenesulfonate of 4-fluoro-2-cyanopyrrolidine derivative |
| 05/18/2006 | US20060106086 Preparation of tegaserod and tegaserod maleate |
| 05/18/2006 | US20060106085 Methods and compositions using PDE4 modulators for treatment and management of central nervous system injury |
| 05/18/2006 | US20060106084 [(1H-indazol-3-yl)methyl]phenols and (hydroxyphenyl)(1H-indazol-3-yl)methanones |
| 05/18/2006 | US20060106083 N-[6-(3-Methylphenyl)-1H-indazol-3-yl]cyclopropanecarboxamide, for example; useful in therapy as agents against a host of diseases caused by and/or associated to a disregulated protein kinase activity; inflammatory conditions, cancer |
| 05/18/2006 | US20060106082 N-[4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenylsulfonyl]-4-nitrooxybutanamide, used for the treatment of inflammatory, cardiovascular, gastrointestinal, respiratory and nervous system disorders, as analgesics, antipyretics and antocoagulants or for organ and tissue preservation |
| 05/18/2006 | US20060106081 Benzimidazole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof |
| 05/18/2006 | US20060106080 Crystal modification II of 2-[2-(1-chloro-cyclopropyl)-3-(2-chlorophenyl)-2-hydroxy-propyl]-2,4-dihydro-3h-1,2,4-triazole-3-thions |
| 05/18/2006 | US20060106079 Reacting methyl 2-methyl-3-(pyrazin-2-yl)-3-oxopropionate with phosphorus pentasulfide in presence of mixed solvent of toluene andxylene under reflux to produce an oltipraz crude crystal; recrystallization; sulfiding, cyclization |
| 05/18/2006 | US20060106078 Prostamide receptor antagonists |
| 05/18/2006 | US20060106077 Pin1-Modulating compounds and methods of use thereof |
| 05/18/2006 | US20060106076 Compositions and methods for the non-invasive treatment of uterine fibroid cells |
| 05/18/2006 | US20060106075 Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity |
| 05/18/2006 | US20060106074 Er-b-selective ligands |
| 05/18/2006 | US20060106073 Process for the preparation of epothilone derivatives, new epothilone derivatives as well as new intermediate products for the process and the methods of preparing same |
| 05/18/2006 | US20060106072 Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors |
| 05/18/2006 | US20060106071 Substituted amides |
| 05/18/2006 | US20060106069 4-(5-Chloro-2-isopropylaminopyridin-4-yl)-1-(toluene-4-sulfonyl)-1H-pyrrole-2-carboxylic acid methyl ester; mitogen-activated protein kinase inhibitor; antiproliferative, anticarcinogenic agent; study of intracellular signal transduction pathways; evaluation of new kinase inhibitors |
| 05/18/2006 | US20060106068 Sigma receptor inhibitors |
| 05/18/2006 | US20060106067 Androgen receptor agonist; prostate cancer, hypogonadism; 4-[4-(hydroxymethyl)-1-piperidinyl]-1-naphthonitrile; 4-(4-hydroxy-2-methyl-1-pyrrolidinyl-1-benzothiophene-7-carbonitrile |
| 05/18/2006 | US20060106066 Benzyl substituted (piperidin-4-yl)aminobenzamido derivatives |
| 05/18/2006 | US20060106065 Methods of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D- glucuitol compounds in combination therapy |
| 05/18/2006 | US20060106064 Butyrophenones and sigma-1 receptor antagonists protect against oxidative-stress |
| 05/18/2006 | US20060106063 dosage forms of pimavanserin tartrate, serotonin receptor antagonists, used for the treatment of psychological disorders |
| 05/18/2006 | US20060106062 Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors |